Electronic Filing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jerome B. Zeldis	Group Art Unit: 1618
Application No.: 13/801,262	Confirmation No.: 4855
Filed: March 13, 2013	Examiner: SAMALA, Jagadishwar Rao
For: METHODS OF TREATING MYELODYSPLASTIC SYNDROMES USING LENALIDOMIDE	Attorney Docket No.: 12827-392-999

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In response to the non-final Office Action mailed April 29, 2014, Applicant respectfully submits the following claim amendments and remarks for consideration by the Examiner and entry into the record of the above-identified application. Also submitted herewith is a Petition for Extension of Time for three months from July 29, 2014 to and including October 29, 2014.

Amendments to the Claims are reflected in a **listing of the claims** that begins on page 2 of this paper.

Remarks begin on page 8 of this paper.

Listing of the Claims:

1-37. (canceled)

38. (new) A method of treating myelodysplastic syndrome, which comprises administering to a patient in need thereof about 1 mg to about 50 mg per day of a compound having the formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

39. (new) The method of claim 38, wherein the myelodysplastic syndrome is refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia.

40. (new) The method of claim 38, wherein the compound is



and is not a pharmaceutically acceptable salt, solvate or stereoisomer.

41. (new) The method of claim 38, wherein the compound is a pharmaceutically acceptable salt.

42. (new) The method of claim 38, wherein the compound is a pharmaceutically acceptable solvate.

43. (new) The method of claim 38, wherein the compound is a pharmaceutically acceptable stereoisomer.

44. (new) The method of claim 38, wherein the patient is not previously treated for a myelodysplastic syndrome.

45. (new) The method of claim 38, wherein the patient has been previously treated for a myelodysplastic syndrome.

46. (new) The method of claim 38, which further comprises administering a therapeutically effective amount of a second active agent.

47. (new) The method of claim 46, wherein the second active agent is dexamethasone.

48. (new) The method of claim 46, wherein the second active agent is azacitidine.

49. (new) The method of claim 38, wherein the compound is administered before, during or after transplanting umbilical cord blood, placental blood, peripheral blood stem cell, hematopoietic stem cell preparation or bone marrow in the patient.

50. (new) The method of claim 38, wherein the compound is administered cyclically.

51. (new) The method of claim 38, wherein compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.

52. (new) The method of claim 38, which comprises cyclically administering the compound until disease progression or unacceptable toxicity.

53. (new) The method of claim 38, wherein the compound is administered in an amount of about 2.5 mg per day.

54. (new) The method of claim 38, wherein the compound is administered in an amount of about 5 mg per day.

55. (new) The method of claim 38, wherein the compound is administered in an amount of about 10 mg per day.

56. (new) The method of claim 38, wherein the compound is administered in an amount of about 15 mg per day.

57. (new) The method of claim 38, wherein the compound is administered in an amount of about 20 mg per day.

58. (new) The method of claim 38, wherein the compound is administered in an amount of about 25 mg per day.

59. (new) The method of claim 38, wherein the compound is administered in an amount from about 5 mg per day to about 25 mg per day for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.

60. (new) The method of claim 38, wherein the compound is administered in an amount of about 10 mg per day or about 15 mg per day for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.

61. (new) The method of claim 38, wherein the compound is administered orally.

62. (new) The method of claim 61, wherein the compound is administered in the form of a capsule or tablet.

63. (new) The method of claim 62, wherein the compound is administered in a capsule in an amount from about 1 mg to about 50 mg.

64. (new) The method of claim 62, wherein the compound is administered in a capsule in an amount of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg or about 25 mg.

65. (new) A method of treating transfusion dependent anemia due to low to intermediate-1-risk myelodysplastic syndrome, which comprises administering to a patient in need thereof about 1 mg to about 50 mg per day of a compound having the formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

66. (new) The method of claim 65, wherein the compound is



and is not a pharmaceutically acceptable salt, solvate or stereoisomer.

67. (new) The method of claim 65, wherein the compound is a pharmaceutically acceptable salt.

68. (new) The method of claim 65, wherein the compound is a pharmaceutically acceptable solvate.

69. (new) The method of claim 65, wherein the compound is a pharmaceutically acceptable stereoisomer.

70. (new) The method of claim 65, wherein the patient is not previously treated for a myelodysplastic syndrome.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.